Skip to content

United Therapeutics

US · UTHR #836 by market cap Listed 1970
554.73 -4.37 -0.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Fair Value how this is computed

Above fair value
366.36 fair value ≈ 446.40 526.47
  • Implied fair-value range of 366.36-526.47, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +24.3% above the average-multiple fair value of 446.40.

Valuation each multiple against its own 5-year range

P/B ratio 3.76 Expensive vs history 93rd percentile
5-year average 2.54 · #51 of 69 in Drug Manufacturers - Specialty & Generic
P/E ratio 20.94 Expensive vs history 96th percentile
5-year average 16.02 · forward 22.54 · #13 of 26 in Drug Manufacturers - Specialty & Generic
P/S ratio 7.41 Expensive vs history 94th percentile
5-year average 5.76 · forward 7.05 · #63 of 79 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
Viatris (VTRS) 22.50B -37.04 1.64 2.45%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value571.69 Economic moatNarrow UncertaintyMedium

Trading 3.1% below Morningstar's fair value estimate.

Fair value

United Therapeutics Corp is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% discount to our quantitative fair value estimate of $571.69 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's balance sheet bolsters our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its debt to EBITDA ratio, which falls in the bottom 1% compared with global peers. Without much debt relative to assets, this company should exhibit high resilience should the global economy weaken; if not, the company could raise debt and invest in the business or return capital to shareholders. We believe this is a sign that shares could be undervalued.

Alternatively, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, falls in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

United Therapeutics discussion 0 comments

Add a comment